- Clinical Trials
- April 2025
- 60 Pages
Global
From €1790EUR$2,000USD£1,564GBP
- Clinical Trials
- April 2025
- 240 Pages
Global
From €2685EUR$3,000USD£2,346GBP
- Drug Pipelines
- April 2025
- 80 Pages
Global
From €1790EUR$2,000USD£1,564GBP
- Drug Pipelines
- April 2025
- 50 Pages
Global
From €1343EUR$1,500USD£1,173GBP
- Drug Pipelines
- April 2025
- 60 Pages
Global
From €1343EUR$1,500USD£1,173GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1343EUR$1,500USD£1,173GBP
- Drug Pipelines
- April 2025
- 60 Pages
Global
From €1119EUR$1,250USD£977GBP
- Report
- December 2024
- 200 Pages
Global
From €3357EUR$3,750USD£2,932GBP
- Report
- May 2024
- 200 Pages
Global
From €3715EUR$4,150USD£3,245GBP
- Report
- July 2024
- 110 Pages
Global
From €4252EUR$4,750USD£3,714GBP
- Report
- April 2023
- 110 Pages
Global
From €4252EUR$4,750USD£3,714GBP
- Report
- October 2022
- 113 Pages
Global
From €4252EUR$4,750USD£3,714GBP
- Report
- August 2024
- 200 Pages
Global
From €3463EUR$3,869USD£3,025GBP
- Report
- April 2025
- 147 Pages
Global
From €3580EUR$3,999USD£3,127GBP
- Report
- March 2025
- 255 Pages
Global
From €2238EUR$2,500USD£1,955GBP
- Report
- February 2025
- 233 Pages
Global
From €2238EUR$2,500USD£1,955GBP
- Report
- January 2024
- 425 Pages
Global
From €3222EUR$3,600USD£2,815GBP
- Report
- January 2024
- 183 Pages
Middle East, Africa
From €1343EUR$1,500USD£1,173GBP
- Report
- January 2024
- 187 Pages
Europe
From €1343EUR$1,500USD£1,173GBP
- Report
- January 2024
- 189 Pages
Asia Pacific
From €1343EUR$1,500USD£1,173GBP

Bispecific antibodies are a type of biotechnology that are used to target two different antigens simultaneously. They are engineered to bind to two different epitopes on the same or different antigens, allowing them to act as a bridge between two different cells or molecules. Bispecific antibodies have been used in a variety of therapeutic applications, including cancer immunotherapy, autoimmune diseases, and infectious diseases.
Bispecific antibodies have the potential to improve the efficacy of existing treatments and to develop new treatments for diseases that have not yet been addressed. They can also be used to target multiple antigens at once, allowing for more efficient and effective treatments.
The bispecific antibodies market is expected to grow significantly in the coming years due to the increasing demand for targeted therapies and the development of new technologies. Companies in the market include AbbVie, Amgen, AstraZeneca, Biogen, Boehringer Ingelheim, Celgene, Genentech, GlaxoSmithKline, Merck, Novartis, and Pfizer. Show Less Read more